Charles River Laboratories International, Inc.

Health Care
Biotechnology: Commercial Physical & Biological Resarch
www.criver.com

Earnings Score
Moat Score
Safety Score
Final Score

Market Cap $10.28B
PE 25
Debt $2.33B
Cash $211.64M
EV $12.40B
FCF $560.48M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$413.08M
EBIT	$527.96M
ROE	11%
ROA	7%
FCF	$560.48M
Equity	$3.79B
Growth Stability	86%
PE	24.89
PEG	1.94
PB	2.71
P/FCF	18.34
P/S	2.53
Price/Cash	0.02
Debt/Equity	0.62
Debt/FCF	4.16
Net Margins	7%
Op. Margins	13%
Earnings CAGR	19%
Sales Growth YoY	-2%
Sales Growth QoQ	-2%
Sales CAGR	15%
FCF CAGR	7%
Equity CAGR	21%
Earnings Stability	0.86
Earnings Growth YoY	-21%
Earnings Growth QoQ	-24%

Earnings CAGR 5Y	13%
Sales CAGR 5Y	11%
FCF CAGR 5Y	-1%
Equity CAGR 5Y	20%
Earnings CAGR 3Y	6%
Sales CAGR 3Y	6%
FCF CAGR 3Y	8%
Equity CAGR 3Y	18%
Market Cap	$10.28B
Revenue	$4.06B
Assets	$8.00B
Total Debt	$2.33B
Cash	$211.64M
Shares Outstanding	51.13M
EV	12.4B
Earnings Score	94%
Moat Score	85%
Safety Score	87%
Final Score	89%
Working Capital	482.5M
Current Ratio	1.48
Shares Growth 3y	1%
Equity Growth QoQ	2%
Equity Growth YoY	14%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

SEC Filings

Direct access to Charles River Laboratories International, Inc. (CRL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 28
- 10-Q Jun 29
- 10-Q Mar 30
2023
- 10-K Dec 30
- 10-Q Sep 30
- 10-Q Jul 01
- 10-Q Apr 01
2022
- 10-K Dec 31
- 10-Q Sep 24
- 10-Q Jun 25
- 10-Q Mar 26

Sector Comparison

How does Charles River Laboratories International, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Charles River Laboratories International, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 19%

Stability 86%

loading chart...

Charles River Laboratories International, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Charles River Laboratories International, Inc..

Years

Calculation mode

= $9.3B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$560M	$601M	$645M	$693M	$743M	$798M	$856M	$919M	$986M	$1.1B	$1.1B	$11B
DCF		$547M	$533M	$520M	$508M	$495M	$483M	$471M	$460M	$449M	$438M	$4.4B
Value	$9.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	10%	11%	9%	7%	10%	10%	12%	11%	12%	11%	7%
ROA	-	10%	9%	10%	9%	7%	8%	8%	9%	8%	7%
ROE	-	20%	18%	12%	17%	15%	17%	15%	16%	13%	11%

Net Margins (7.42%)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	3.84	4.74	4.86	5.54	5.62	5.3	5.01	9.19	7.26	4.16
Debt over Equity	1.16	1.17	1.48	1.09	1.26	1.17	0.95	1.05	0.91	0.74	0.62
Growth Stability	-	-	-	86%	100%	100%	100%	100%	100%	100%	86%

Bad Debt/FCF ratio (4.16)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.62)

The company is not overleveraged and has a good balance between equity and debt.

Neutral Graham’s Stability (86%)

The company has a stability in its earnings that is not too good nor too bad.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	5%	23%	10%	22%	16%	12%	21%	12%	4%	11%
Earnings YoY growth	-	18%	4%	-20%	84%	11%	45%	7%	24%	-2%	13%
Equity YoY growth	-	9%	14%	25%	26%	24%	29%	20%	17%	21%	20%
FCF YoY growth	-	15%	16%	-10%	28%	13%	12%	40%	-45%	24%	-1%